Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: A one-year study

被引：44

作者：

Diokno A. ^{[1
]}

Sand P. ^{[2
]}

Labasky R. ^{[3
]}

Sieber P. ^{[4
]}

Antoci J. ^{[5
]}

Leach G. ^{[6
]}

Atkinson L. ^{[7
]}

Albrecht D. ^{[7
]}

机构：

[1] William Beaumont Hospital, Royal Oak, MI, 48073

[2] Evanston Continence Center, Evanston, IL

[3] University of Utah School of Medicine, Salt Lake City, UT

[4] Urological Associates of Lancaster, Lancaster, PA

[5] Urology Specialists, Waterbury, CT

[6] Tower Urology Institute, Los Angeles, CA

[7] ALZA Corporation, Mountain View, CA

来源：

International Urology and Nephrology | 2002年 / 34卷 / 1期

关键词：

Cholinergic antagonists; Oxybutynin; Preparations; Sustained-release; Urinary incontinuse; Xerostomia;

D O I：

10.1023/A:1021372426421

中图分类号：

学科分类号：

摘要：

In this multicenter, open-label study of extended- and immediate-release oxybutynin chloride, community-dwelling participants were studied for up to 12 months to evaluate the long-term safety profile of extended-release oxybutynin. Quality-of-life assessments designed to measure the impact of incontinence and evaluate treatment outcome were used to study subjective improvement. A total of 904 women and 163 men (mean age 64 years, range 29-91 years) were enrolled. The majority of discontinuations were in the first 3 months (25.5%); of those who continiued after 3 months, 62% remained on extended-release oxybutynin chloride for one year. The majority of discontinuations were for adverse events; dry mouth was the most frequently cited event leading to discontinuation (8.4%). Significant improvements weere seen in QOL measures. Long-term therapy with extended-release oxybutynin chloride was generally well tolerated and effective, improving quality of life significantly in participants with overactive bladder ove 3-12 months of therapy.

引用

页码：43 / 49

页数：6

共 14 条

[1] Jackson S., The patient with an overactive bladder - Symptoms and quality-of-life issues, Urology, 50, pp. 18-22, (1987)
[2] Wein A.J., Rovner E.S., The overactive bladder: An overview for primary health care providers, Int J Fertil Womens Med, 44, pp. 56-66, (1999)
[3] Brown J.S., Subak L.L., Gras J., Et al., Urge incontinence: The participant's perspective, J Womens Health, 7, pp. 1263-1269, (1998)
[4] Norton P.A., MacDonald L.D., Sedgewick P.M., Stanton S.L., Distress and delay associated with urinary incontinence, frequency, and urgency in women, BMJ, 297, pp. 1187-1189, (1988)
[5] Yarker Y.E., Goa K.L., Fitton A., Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability, Drugs & Aging, 6, pp. 243-262, (1995)
[6] Anderson R., Mobley D., Blank B., Et al., Once-a-day controlled-release versus immediate-release oxybutynin chloride in the treatment of urinary urge incontinence, J Urol, 161, pp. 1809-1812, (1999)
[7] Gleason D.M., Susset J., White C., Et al., Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence, Urology, 54, pp. 420-423, (1999)
[8] Ware J.E., Sherbourne C.D., The MOS 36-Item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection, Medical Care, 30, pp. 473-483, (1992)
[9] Davila G.W., Primozich J., Shapiro H., Quality of life assessment in urinary incontinence: Evaluation of a disease-specific, patient-specific, short-form questionnaire, Drug Information Journal, 31, pp. 1416-1417, (1997)
[10] Schumaker S.A., Wyman J.F., Uebersax J.S., Et al., Health-related quality of life measures for women with urinary incontinence: The Incontinence Impact Questionnaire and the Urogenital Distress Inventory, Quality of Life Research, 3, pp. 291-306, (1994)

← 1 2 →